Individualized Angiotensin-Converting Enzyme (ACE)-Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk Model
about
Integrating clinical decision support systems for pharmacogenomic testing into clinical routine - a scoping review of designs of user-system interactions in recent system development.Cardiovascular pharmacogenetics: a promise for genomically-guided therapy and personalized medicine.Pharmacogenetic Risk Scores for Perindopril Clinical and Cost Effectiveness in Stable Coronary Artery Disease: When Are We Ready to Implement?
P2860
Individualized Angiotensin-Converting Enzyme (ACE)-Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk Model
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 March 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Individualized Angiotensin-Con ...... l GENEtic (PERGENE) Risk Model
@en
Individualized Angiotensin-Converting Enzyme
@nl
type
label
Individualized Angiotensin-Con ...... l GENEtic (PERGENE) Risk Model
@en
Individualized Angiotensin-Converting Enzyme
@nl
prefLabel
Individualized Angiotensin-Con ...... l GENEtic (PERGENE) Risk Model
@en
Individualized Angiotensin-Converting Enzyme
@nl
P2093
P2860
P356
P1476
Individualized Angiotensin-Con ...... l GENEtic (PERGENE) Risk Model
@en
P2093
A H Jan Danser
Goran Rudez
Jasper J Brugts
K Martijn Akkerhuis
Laura C Van Vark
Michel E Bertrand
Moniek de Maat
PERGENE investigators
Roberto Ferrari
P2860
P304
P356
10.1161/JAHA.115.002688
P577
2016-03-28T00:00:00Z